In cultured primary microglia from neonatal rat spinal cords, GW9508 increased POMC expression in a concentration-dependent manner, with an EC50 value of 13.4 μM. In senescent iTECs, GW9508 at 4.8 μM decreased the proportion of SA‐β‐gal positive cells from approximately 85% in the DOX‐treated group to about 20%. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
POMC expression in cultured primary microglia
Cell-based study · cultured primary microglia; spinal cords of 1-day-old neonatal rats [1]
Cultured primary microglia from neonatal rat spinal cords were incubated with GW9508 for 2 h. Treatment increased POMC expression in a concentration-dependent manner, with an EC50 value of 13.4 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- 2 h
- Method
- GW9508 incubation
- Vehicle
- normal saline
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: GW9508
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Drugs and reagents (S5); Results > GW9508 stimulated IL-10 and β-endorphin expression in cultured primary microglia and astrocytes (S157, S159, S160, S163, S164)
mRNA expression of IL-10, POMC, and PDYN; quantitative real-time PCR: mRNA expression of IL-10, POMC, and PDYN; quantitative real-time PCR; comparator: control group — Results > GW9508 stimulated IL-10 and β-endorphin expression in cultured primary microglia and astrocytes (S159, S164)
SA‐β‐gal positivity in senescent thymic epithelial cells
Cell-based study · senescent iTECs; n = 3 [2]
Senescent iTECs were treated with GW9508 at 4.8 μM. The proportion of SA‐β‐gal positive cells decreased from approximately 85% in the DOX‐treated group to about 20% with GW9508 treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 4.8 μM
- Exposure duration
- 36 h; GW9508 treatment for 72 h
- Co-treatment
- Other interventions in this design: Doxorubicin (DOX, 25316‐40‐9, MedChemExpress, USA) 150 ng/mL. Compound effect isolated by the comparison: from approximately 85% in the DOX‐treated group to about 20%.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: GW9508
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Cell Culture (S16); Materials and Methods > SA‐β‐Gal Assay (S39); Results > GW9508 Enhanced the Viability of Senescent iTECs (S111, S114, S115); FIGURE 3 legend (S179, S187)
quantification of SA‐β‐gal positive cells: quantification of SA‐β‐gal positive cells; comparator: DOX‐treated group — Results > GW9508 Enhanced the Viability of Senescent iTECs (S115); FIGURE 3 legend (S179)